Cola declined on Tuesday after the soda maker posted a mixed second-quarter print.Adjusted earnings of 87 cents a share ...

AstraZeneca plans to invest $50B in its U.S. footprint by 2030. Some of that will be directed to a new GLP-1 manufacturing facility in Virginia.

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.